Biobanking, Clinical Trials and Genetic Disease

Why early participant engagement is now a top priority in genetic disease research

pharmaphorum

JANUARY 18, 2023

Pharmaceutical companies and biotechs are also adapting their approaches, launching patient finding and engagement programmes that can start years before clinical trials begin and allow them to run ‘recontact by genotype’ studies that the Resilience Project would have liked to do. Giving participants something in return.

Genetic Disease

Genetic Disease Genetics Research Genome

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

XTalks

APRIL 15, 2021

million people in the US, yet there is no treatment for the most common form of the disease: heart failure with preserved ejection fraction (HFpEF). A lack of efficacy is the greatest reason for clinical trial failures, especially in Phase II and Phase III,” says Dr. Tyl. Heart failure affects about 6.2

Development

Development Drugs Genome Genomics

Clinical Research Informer

Why early participant engagement is now a top priority in genetic disease research

HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development

Webinars

Stay Connected